- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Hitesh Kumar Maheshwari joins Ipca Labs as President - RnD (Formulations)
Mumbai: Ipca Labs has appointed Hitesh Kumar Maheshwari as President – R&D (Formulations) with effect from 16th October, 2023.
"He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the Company," Ipca Labs informed in a BSE filing.
Hitesh Maheshwari, aged 49 years has completed his B. Pharm from Devi Ahilya Vishwavidyalaya, Indore and M.Pharm from Panjab University, Chandigarh. Maheshwari brings with him a professional experience of over 24 years. He started his career with Ranbaxy Laboratories in the year 1999 and thereafter worked with Zydus Cadila Healthcare Ltd., Hikma Pharmaceuticals Ltd., Astron Research Ltd. and Macleods Pharmaceuticals Ltd.
Prior to joining Ipca, he was associated with Torrent Pharmaceuticals Ltd. as Executive Director and Head – R&D (Formulations).
Medical Dialogues team had earlier reported that the company's shareholders had approved the re-appointment of Pranay Godha as the Managing Director of the Company with effect from 11th November, 2023 for the period of five years till 10th November, 2028.
Read also: Ipca Labs shareholders approve re-appointment of Pranay Godha as MD
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The Company was founded by group of businessmen and medical professionals in 1949. It produces theobromine, acetyl thiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally. Ipca is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments.
Read also: Ipca Labs buys 33.38 percent stake in Unichem for over Rs 945 crore
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751